Fabry Disease

Type: Keyphrase
Name: Fabry Disease
First reported Jul 19 2014 - Updated Jul 20 2014 - 1 reports

Shire sales growth shows why AbbVie was attracted

In what could be its penultimate set of financials before being merged into AbbVie, Shire has posted a strong set of second-quarter figures.Operating income jumped 32% to $630 million, while revenues rose 20% to $1.50 billion. Turnover was again driven ... [Published Pharma Times - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 2 reports

AbbVie finally gets Shire, its low tax base and enough new drugs to protect its future

Companies agree on £32 billion and a big old bonus for Shire CEO OrnskovShareToolsWith a bid reaching nearly $55 billion and some goodies for the top execs, AbbVie ($ABBV) was finally able to get Ireland-based Shire ($SHPG) to surrender its independence, ... [Published FiercePharma - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Federal Trade Commission Urged to Probe Sanofi (France) & Over A "Conspiracy"

Two years ago, Shire issued two announcements about its medicine for treating Fabry disease, a rare affliction that causes a buildup of fatty material in the autonomic nervous system, eyes, kidneys and cardiovascular system. On the surface, the announcements ... [Published BioSpace - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 2 reports

Conspiracy Theory Posited Over Shire’s Withdrawal Of BLA For Fabry Disease Drug

Knowledge Ecology International suggests Shire pulled its Replagal BLA in return for rights to Mount Sinai School of Medicine patent that could have blocked sales in Europe; asks FTC to investigate “possible conspiracy” between school, Shire and...Related ... [Published BioPortfolio - Jul 16 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Industry trims support for CME

An advocacy group alleges that Shire's decision to ignore the US Fabry disease market was the result of a backroom deal with Sanofi.Novartis and the nonprofit Banner Alzheimer's Institutes are testing a theory that treating healthy patients could prevent ... [Published Medical Marketing And Media - Jul 15 2014]
First reported Jul 05 2014 - Updated Jul 05 2014 - 1 reports

Key Stocks With Insiders Buying This Week

In what was a historic week for the stock markets, with all the big indexes hitting all-time highs, that didn’t stop insiders from stepping up to the plate to purchase more stock. For investors, aggressive insider buying at the top range of a secular ... [Published 24/7 Wall St - Jul 05 2014]
First reported Jul 01 2014 - Updated Jul 02 2014 - 1 reports

Janney Capital Upgrades Amicus Therapeutics, Inc. Stock To Buy

In a research note issued today, Janney Capital analyst Kimberly Lee upgraded shares of Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) from Hold to Buy and raised her price target to $5.00 (from $2.50) after FOLD provided updates and detailed the statistical ... [Published Value Walk - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Up 20%: Time to Buy Amicus Therapeutics, Inc?

By | More ArticlesIn biotech, when you hear that a drug's peak sales estimates hover around $200 million, usually you shrug. But for a stock like Amicus Therapeutics (NASDAQ: FOLD Amicus announced yesterday that it would be reporting data from its phase ... [Published Motley Fool - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Amicus Therapeutics Surging On Phase 3 Plan Announcement

Amicus Therapeutics ( FOLD ) provided a detailed statistical analysis plan including updates on the company’s second Phase 3 study of its experimental drug, migalastat. The new study, titled Study 012, will further test migalastat as a monotherapy for ... [Published Bidness Etc - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese ...

In Taiwan, DNA-based newborn screening showed a surprisingly high incidence of a cardiac Fabry mutation (IVS4 + 919G A). The prevalence of this mutation is too high to be believed that it is a real pathogenic mutation.The purpose of this study is to identify ... [Published 7thSpace - Jul 01 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Sector Update: Healthcare Stocks Losses Accelerate...

PFE -0.02%ABT +0.76%MRK +0.40%AMGN -0.26%Healthcare stocks slightly lower today were with the NYSE Healthcare Sector Index slipping about 0.3% and shares of healthcare companies in the S&P 500 also down about 0.5% as a group.In company news, Amicus Therapeutics ... [Published Nasdaq - Jun 30 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012

Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q1496% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment ExtensionStatistical Analysis Plan FinalizedCRANBURY, N.J., June 30, 2014 ... [Published CW Atlanta - Jun 30 2014]

Quotes

"The Board of Protalix and myself are pleased to have Mr. Yanai join our Board as Chairman," stated Mr. Bronfeld. "He brings extensive knowledge and vast experience from his years as CEO at Teva Pharmaceutical Industries and Makhteshim Agan, which will be helpful in further guiding Protalix. We look forward to his leadership as Chairman."
The answer was simple, coming straight from AbbVie's CEO: "We wouldn't be doing it if it was just the tax impact."
"I think we are almost there," said Alistair Campbell, an analyst at Berenberg Bank in London. "Due diligence should be done and a deal is going to be done pretty much at this level. It's pretty straightforward from here."
"We're creating a unique, diversified biopharmaceutical company," AbbVie's chief executive, Richard Gonzalez, said in a statement. "The combined company would benefit from a best-in-class product development platform, a stronger pipeline and more enhanced R&D capabilities."

More Content

All (58) | News (53) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Glucocerebrosidase Is Shaking Up the Synucleino... [Published General Medicine eJournal - Jul 25 2014]
Protalix BioTherapeutics Names Shlomo Yanai as ... [Published Stock Nod - Jul 24 2014]
Shire's Q2 Earnings Strong but Overshadowed b… [Published Zacks.com - Jul 22 2014]
AbbVie Acquires Shire To Reincorporate In U.K. [Published Bioresearch Online - Jul 21 2014]
Welcome to Ireland, AbbVie [Published Motley Fool Discussion Boards - Jul 21 2014]
AbbVie Gets Its 'Tax Break' In Shire [Published Seeking Alpha - Jul 21 2014]
Shire sales growth shows why AbbVie was attracted [Published Pharma Times - Jul 19 2014]
AbbVie achieves tax coup by pouncing on British... [Published This Is Money - Jul 18 2014]
AbbVie finally gets Shire, its low tax base and... [Published FiercePharma - Jul 18 2014]
Shire agrees to £31bn takeover by US firm AbbVie [Published Mail Online UK - Jul 18 2014]
SHIRE VALUED AT £31BN AMID TAKEOVER [Published Mail Online UK - Jul 18 2014]
Federal Trade Commission Urged to Probe Sanofi... [Published BioSpace - Jul 16 2014]
Conspiracy Theory Posited Over Shire’s Withdraw... [Published BioPortfolio - Jul 16 2014]
Conspiracy Theory Posited Over Shire’s Withdraw... [Published Health News Daily - Jul 16 2014]
Industry trims support for CME [Published Medical Marketing And Media - Jul 15 2014]
AbbVie coaxes Shire into discussions with sweet... [Published PMLive - Jul 14 2014]
Shire confirms talks with US drug firm AbbVie o... [Published Guardian.co.uk - Jul 11 2014]
14 Insanely Important Biotech/Drug Trading Cata... [Published TheStreet.com - Jul 10 2014]
14 Insanely Important Biotech/Drug Trading Cata... [Published The Street Latest - Jul 10 2014]
Doctors offer new minimally invasive system to ... [Published News-Medical.Net - Jul 09 2014]
Scientists discover new compounds that could al... [Published News-Medical.Net - Jul 08 2014]
Amicus Therapeutics Analyst Report; Solid Pipel... [Published CBS Detroit - Jul 07 2014]
Amicus Therapeutics Analyst Report; Solid Pipel... [Published Financial Services - Jul 07 2014]
Key Stocks With Insiders Buying This Week [Published 24/7 Wall St - Jul 05 2014]
Multiple Insiders of Amicus Therapeutics, Inc. ... [Published TradingCharts.com - Jul 02 2014]
Up 20%: Time to Buy Amicus Therapeutics, Inc? [Published Motley Fool - Jul 01 2014]
Amicus Up on Migalastat Study Update [Published Yahoo! Finance - Jul 01 2014]
Why Amicus Therapeutics (FOLD) Stock Continues ... [Published TheStreet.com - Jul 01 2014]
Why Amicus Therapeutics (FOLD) Stock Continues ... [Published The Street Latest - Jul 01 2014]
Janney Capital Upgrades Amicus Therapeutics, In... [Published Value Walk - Jul 01 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Global Fabry Disease Pipe... [Published Business Wire Health News - Jun 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xs3qs6/fabry_disease) has announced the addition of the "Fabry Disease Pipeline Highlights - 2014 Update" report to their offering. The latest report Fabry Disease ...
Research and Markets: Fabry Disease - Pipeline ... [Published Business Wire Health News - Jun 10 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fhx488/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information ...
Orphan designation: 1-Deoxygalactonojirimycin h... [Published Orphan designations - May 08 2014]
[tt] [GRG] Pompe's Disease [Published TranshumanTech - Jan 27 2014]
To Members and Friends of the Los Angeles Gerontology Research Group:         Pompe's Disease... -- Steve Coles "Agonizing Choices for Lives Saved by Miracle Drugs" by Geeta AnandSeven months ago, Megan Crowley made a gutsy decision: to undergo ...
1

Press Releases

sort by: Date | Relevance
Amicus Therapeutics Analyst Report; Solid Pipel... [Published Financial Services - Jul 07 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.